Two HIV drugs Dovato (dolutegravir + lamivudine) and Pifeltro (doravirine) will be added to the NHI reimbursement price list on January 22. A key health ministry panel approved their fast-tracked listing on January 15. ViiV Healthcare’s Dovato, a fixed-dose combination…
To read the full story
Related Article
- HIV Med Pifeltro Now Available in Japan: MSD
February 18, 2020
- Japan Approves 2 HIV Drugs, Listing Expected Soon
January 15, 2020
REGULATORY
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
- MHLW Eyes Limited Charge Exemptions for OTC-Like Topical Drugs
July 24, 2026
- MHLW Panel Voices Disappointment over Efluelda Launch Delay
July 24, 2026
- Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





